www.stocktitan.net


Klotho Neurosciences, Inc. is expanding its development focus beyond neurodegenerative disorders to include complementary longevity and anti-aging technologies. The company is evaluating acquisitions and assembling a multidisciplinary team to target key biomolecules—such as alpha- and beta-Klotho, FOXO3, and anti-myostatin—to develop interventions aimed at preserving cognitive function, muscular strength, bone health, and overall organ health to delay age-related diseases.

Key points

  • Deployment of proprietary KLTO-101 and KLTO-202 gene therapy candidates targeting neurodegenerative pathways, now advancing into broader anti-aging applications.
  • Assembly of a multidisciplinary scientific team to evaluate biomolecular targets—including alpha-Klotho, beta-Klotho isoforms, FOXO3 transcription factors, and anti-myostatin—for longevity interventions.
  • Strategic acquisition approach to integrate complementary technologies aimed at preserving cognitive function, muscle mass, bone density, and organ health across multiple age-related diseases.

Why it matters: This expansion leverages Klotho’s multimodal aging pathways to pioneer next-generation longevity therapeutics with the potential to delay multiple age-related diseases.

Q&A

  • What is the Klotho gene?
  • What are alpha-Klotho and beta-Klotho?
  • How does FOXO3 influence aging?
  • What is anti-myostatin therapy?
Copy link
Facebook X LinkedIn WhatsApp
Share post via...
Klotho Expands into Multi-Organ Anti-Aging Drug Development | KLTO Stock News

Klotho Neurosciences has demonstrated that their adeno-associated virus (AAV9) platform delivers the secreted form of the Klotho protein (s-KL) to increase circulating levels, resulting in a 20% extension of healthy lifespan in mice. Building on foundational work linking Klotho to aging, this approach targets multiple age-associated pathologies—including cognitive decline, neuroinflammation, sarcopenia, and osteoporosis—offering a unified therapeutic strategy.

Key points

  • AAV9-mediated delivery of secreted Klotho (s-KL) increases mouse lifespan by 20%.
  • Overexpression of full-length Klotho gene extends murine lifespan by 30–40%.
  • s-KL therapy mitigates cognitive decline, neuroinflammation, sarcopenia, and osteoporosis.

Why it matters: Demonstrating a single protein-based therapy that extends healthy lifespan and ameliorates multiple age-related diseases marks a paradigm shift in anti-aging therapeutics.

Q&A

  • What is the secreted form of Klotho (s-KL)?
  • How does AAV9 delivery work in this context?
  • Which age-related conditions might benefit from s-KL therapy?
  • Why is Klotho considered a master regulator of aging?
Copy link
Facebook X LinkedIn WhatsApp
Share post via...
KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO") | KLTO Stock News